KANEKA
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii; hereinafter "Kaneka")(TOKYO:4118) has announced that its "Green Planet foam molded product" using KANEKA Biodegradable Polymer Green PlanetTM (hereinafter "Green Planet") has been adopted by Sony Corporation (Headquarters: Minato-ku, Tokyo; hereinafter "Sony") as a cushioning material for its large-screen televisions. The material will be used for 85-inch BRAVIATM television to be released this summer*1. To ensure shock resistance for large, heavy televisions during transportation, a certain level of strength and durability is required. Using Sony's technical expertise in packaging design and Kaneka's material molding technology, the two companies conducted a series of technical verifications to realize the use of Green Planet's foam molded product as cushioning materials. This is a world first*2 for Green Planet foam molded products to be used as cushioning materials for home electric appliances.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422034858/en/
BRAVIA packaging materials using Green Planet and image of use (Photo: Business Wire)
Green Planet is a 100% biomass-derived biodegradable biopolymer developed by Kaneka based on our desire to provide environmentally friendly solutions that do not depend on petroleum resources. It has excellent biodegradability in a wide range of environments and easily decomposes in soil and seawater, returning to CO2 and water, thus contributing to solving environmental pollution problems caused by plastics. The Green Planet foam molded product is the result of combining our long-cultivated foam molding technology with Green Planet's development technology, and will be used in a wide range of cushioning material applications, such as packaging for home electric appliances, transportation containers for fresh food, and materials for the fishing industry.
Based on our mission of "KANEKA thinks 'Wellness First'.", Kaneka provides value globally as a solution provider. We will continue to strive for the realization of a sustainable society by promoting the use of Green Planet.
*1. |
For Hong Kong and Taiwan. Depending on area and model. |
"Sony" and "BRAVIA" are registered trademarks or trademarks of Sony Group Corporation or its affiliates. |
|
*2. |
As a cushioning material produced by Kaneka using Green Planet (based on research by Kaneka, as of April, 2024) |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422034858/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)16.2.2025 00:00:00 CET | Press release
OBODENCE™ and XBRYK™ approved by the European Commission (EC) for all indications referencing Prolia and Xgeva, respectivelyMarks Samsung Bioepis’ 10th and 11th product and first endocrinology treatment approved by the EC – adding to its growing portfolio of biosimilars Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars referencing Prolia and Xgeva – formerly referred to as SB16. OBODENCE, referencing Prolia, has been approved for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. XBRYK, referencing Xgeva, has been approved for the prevention of skel
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)15.2.2025 00:50:00 CET | Press release
In the MOTION Phase 3 study, ROMVIMZA met primary endpoint of improved objective response rate (ORR) compared to placebo and all key secondary endpoints with statistically significant and clinically meaningful improvements in quality-of-life measures, and demonstrated well-tolerated safety profile Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214768549/en/ “
Venture Global, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call14.2.2025 19:17:00 CET | Press release
Venture Global, Inc. (“Venture Global”)(NYSE: VG) announced today that it plans to issue its earnings release with respect to fourth quarter and full year 2024 financial results before market open on Thursday, March 6, 2025. Venture Global will host a conference call for investors and analysts beginning at 9:00 am Eastern Time (ET) on March 6, 2025, to discuss fourth quarter and full year results and provide guidance for the 2025 fiscal year. A listen-only webcast of the call and accompanying slide presentation will be available at Venture Global’s Investor Relations website HERE. After the conclusion of the webcast, a replay will be made available on the Venture Global website. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s fir
Asa Gudmundsdottir Wright Award Presented as Plans for New Icelandic Academy of Science & Innovation Announced14.2.2025 17:35:00 CET | Press release
Recognizing Contributions to Science and Innovation Iceland’s President, Halla Tomasdottir, presented the Asa Gudmundsdottir Wright Award at a ceremony at the presidential residence. This year’s recipients are G. Fertram Sigurjonsson, Founder and CEO of Kerecis, and Jon Atli Benediktsson, Rector of the University of Iceland. The award honors individuals who have made significant contributions to science and innovation in Iceland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214199674/en/ President Halla Tomasdottir and Kerecis Founder and CEO Fertram Sigurjonsson (Photo: Business Wire) During the ceremony, plans were also announced for the establishment of the Icelandic Academy of Science & Innovation, into which the award recipients will be inducted as members. The academy will provide a platform for collaboration between researchers, entrepreneurs, industry representatives, and academia. It will uphold the tradition o
Riskified To Report Fourth Quarter and Full-Year 2024 Financial Results on Wednesday, March 514.2.2025 17:33:00 CET | Press release
Riskified Ltd. (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced it will release its fourth quarter and full-year 2024 financial results before the market opens on March 5, 2025. On that day management will host a conference call and webcast at 8:30 a.m. ET to discuss the company's business and financial results. Riskified Fourth Quarter and Full-Year 2024 Financial Results Conference Call When: Wednesday, March 5, 2025 Time: 8:30 a.m. ET Dial-in: To access the conference call via telephone, please register via this registration link and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. Webcast: A live and archived webcast of the conference call will be accessible from the “Events & Presentations” section of the Company’s Investor Relations website at https://ir.riskified.com/. About Riskified Riskified (NYSE:RSKD) empowers businesses to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom